Serum Biomarkers for Risk Stratification of Prostate Cancer Patients on Active Surveillance by Untargeted 1H MRS Metabolomics

HRMAS 1H MRS was employed for an untargeted investigation of metabolism in prostate cancer patients on AS (n=52). Serum samples from two matched patient groups, progressive (n=26) and non-progressive (n=26) were measured with short and long T2 filter to investigate metabolites in the lipoprotein and LMWM regions respectively. PCA on 46 ROI from data acquired by HRMAS 1H MRS with short T2 resulted in a metabolomic profile, PC7, that separated the progressive and non-progressive groups (p = 0.0323). The findings of such studies could revolutionize healthcare by improving the diagnosis of diseases and contributing to multi-omics integration for precision medicine.